CD200 (CD200 Molecule)

Flow cytometric immunophenotyping demonstrated bright CD45 expression with low side scatter and positivity for CD19, CD20, CD38, CD5, CD79b, and FMC7 with negativity for CD34, CD23, CD200, and CD10, suggesting blastoid transformation of MCL rather than de novo ALL. This case highlights the critical role of flow cytometry in distinguishing blastoid MCL from acute leukemia, thereby preventing misdiagnosis and ensuring appropriate therapeutic decision-making.

Functional validation in multiple murine tumor models demonstrated that CD200+ B cells are essential for optimal anti-tumor immunity and critical for the efficacy of anti-PD-1 therapy. Together, our findings provide a high-resolution landscape of B and plasma cells in breast cancer and highlight CD200+ tumor-associated B cells as promising biomarkers and potential therapeutic targets to improve immunotherapy outcomes.

c/EBPβ-mediated suppression of the CD200/CD200R1 signaling pathway represents one potential mechanism in promoting microglial activation and neuroinflammation in the spinal cord of CIBP mice, which provides a potential therapeutic target for CIBP management.

These results demonstrate that cross-species exome capture provides a means to identify genomic alterations that may play a role in the molecular pathogenesis of UGC in the CSL and adds to the body of evidence for an association between OtHV-1 and UGC in this species.

Moreover, treated mice showed increased activation of CD8+ T cells in draining lymph nodes and enhanced tumor infiltration by T cells and natural killer (NK) cells, alongside a marked reduction in immunosuppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). These findings highlight the need for further studies to validate and better understand the therapeutic potential of this combination approach in breast cancer.

In conclusion CD25 and CD200 immunophenotypic co-expression was associated with unfavorable cytogenetic risks, lower rates of complete remission following induction therapy, reduced OS, DFS, and higher mortality rates. Given the limited sample size, subgroup imbalance, and wide confidence intervals, these findings should be interpreted cautiously as exploratory associations and hypothesis-generating and cannot confirm an independent prognostic role for CD25/CD200 co-expression.

Additionally, single-cell RNA-sequencing demonstrates that Ehf expression is highly enriched in CCR7hi DCs in mice and humans. Our study thus reveals a conserved transcriptional program that regulates cDC maturation and immunosuppression.

Targeting the CD200-mediated dormant niche in combination with chemotherapy and immune check point blockade (ICB) significantly eradicated the dormant tumor cells. These insights provide mechanistic understanding of tumor dormancy and treatment options for ICB relapse.

NGS revealed that a common progenitor cell with BCL2-IgH translocation and mutations in TP53, KMT2A, KMT2C, and KMT2D gave rise to two distinct subclones: one (CD5 + CD23+CD200+) CLL driven by mutations in TNFAIP3 and BCORL1, and the other (CD5-CD23-CD200-) driven by mutations in EP300, NOTCH1, and BCL2. This case highlights the significance of clonal heterogeneity in CLL and underscores the crucial role of MFC, flow sorting, and molecular genetics in diagnosing and understanding the complex evolution of this disease.

The obtained results confirm an increased immunoactivation profile in children with VLS, characterized by elevated checkpoint expression and increased levels of proinflammatory cytokines. The studied parameters show potential as diagnostic and prognostic biomarkers, which may constitute the basis for the development of new diagnostic tools and targeted therapeutic strategies in VLS in pediatric patients.

Compared with non-APL-AML patients, APL patients (PML-RARα (S-type) and PML-RARα (L-type)) exhibit unique immunophenotypic changes. The expression frequencies of CD56, CD2, CD34, and CD200 in leukemia cells are significantly correlated with the OS of APL patients, and the high expression of these indicators before treatment may be an adverse prognostic factor for APL patients.